SCHEMBL445209

SCHEMBL445209

NC1(N)[CH]CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2063982 0.97
SCHEMBL38654631 0.69
SCHEMBL960841 0.67
SCHEMBL168533 0.67
SCHEMBL11109306 0.65
SCHEMBL11773209 0.65
SCHEMBL1397180 0.65
SCHEMBL217094 0.65
SCHEMBL11772539 0.65
SCHEMBL11770995 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4161904-A1 INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF TOLVAPTAN AND ITS DERIVATIVES Cambrex Profarmaco Milano S.r.l. (IT) 2023-04-12 EP claimed
WO-2021249877-A1 INTERMEDIATES AND PROCESSES FOR THE PREPARATION OF TOLVAPTAN AND ITS DERIVATIVES CAMBREX PROFARMACO MILANO S.R.L. (IT) 2021-12-16 WO claimed
CN-110054743-A Solvent-free multicomponent system 赢创德固赛有限公司 2019-07-26 CN claimed
EP-2800734-A1 NONIONIC SURFACTANT COMPOSITIONS Dow Global Technologies LLC (US) 2014-11-12 EP claimed
WO-2013123153-A1 NONIONIC SURFACTANT COMPOSITIONS DOW GLOBAL TECHNOLOGIES LLC (US) 2013-08-22 WO claimed
US-7858641-B2 melanocortin-4 receptor (MC4-R) agonists such as (3R,5S)-N-(2-{2-[2-fluoro-4-(methyloxy)phenyl]ethyl}-1-oxo-1,2-dihydroisoquinolin-6-yl)-3,5-dimethyl-N'-[(1S,2S,3S,5R)-2,6,6-trimethylbicyclo[3.1.1]hept-3-yl]piperazine-1-carboximidamide, used for the treatment of obesity or diabetes NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-12-28 US claimed
US-7456183-B2 Guanidino compounds NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-11-25 US claimed
US-7189727-B2 Guanidino compounds CHIRON CORPORATION (US) 2007-03-13 US claimed
EP-1385823-B1 GUANIDINO COMPOUNDS AS MELANOCORTIN-4 RECEPTOR (MC4-R) AGONISTS CHIRON CORP (US) 2006-12-13 EP claimed
US-6960582-B2 Guanidino compounds CHIRON CORPORATION (US) 2005-11-01 US claimed
US-20050124652-A1 Guanidino compounds BOYCE RUSTUM (US) 2005-06-09 US claimed
US-20050038027-A1 Novel guanidino compounds CHIRON CORPORATION 2005-02-17 US claimed
US-20040248895-A1 Novel guanidino compounds CHU DANIEL (US) 2004-12-09 US claimed
EP-1478626-A2 GUANIDINO COMPOUNDS CHIRON CORPORATION (US) 2004-11-24 EP claimed
EP-1440137-A2 METHOD The Associated Octel Company Limited (GB) 2004-07-28 EP claimed
US-6716840-B2 AGONISTS OF THE MELANOCORTIN-4 RECEPTOR (?MC-4R?); USEFUL TREATING OBESITY AND TYPE 2 DIABETES CHIRON CORPORATION 2004-04-06 US claimed
US-20040024211-A1 Novel guanidino compounds CHIRON CORPORATION 2004-02-05 US claimed
US-20030195187-A1 Guanidino compounds CHIRON CORPORATION 2003-10-16 US claimed
WO-2003066597-A2 GUANIDINO COMPOUNDS CHIRON CORPORATION (US) 2003-08-14 WO claimed
WO-2003038015-A2 METHOD THE ASSOCIATED OCTEL COMPANY LIMITED (GB) 2003-05-08 WO claimed